Showing 701-710 of 1321 results for "".
- Desert Harvest's Aloe Glide Receives NEA Seal of Acceptancehttps://practicaldermatology.com/news/desert-harvests-aloe-glide-receives-nea-seal-of-acceptance/2461056/Desert Harvest’s Aloe Glide has received the National Eczema Association (NEA) Seal of Acceptance, making it the first sexual lubricant to earn this seal. The NEA Seal appears on products approved by the association to help consumers identify and choose products that are suitable
- Nevisense Boosts Clinician Confidence in Early Melanoma Diagnosishttps://practicaldermatology.com/news/nevisense-boosts-clinicians-confidence-in-early-melanoma-diagnosis/2461053/Nevisense provides valuable diagnostic guidance for clinicans when evaluating atypical pigmented skin lesions, according to a new study. The Nevisense method uses small electrical impulses to detect cellular irregularities beneath the skin’s surface. In the pilot study,
- L'Oréal and Verily Partner to Advance Precision Skin Healthhttps://practicaldermatology.com/news/loreal-and-verily-partner-to-advance-precision-skin-health/2461048/L'Oréal and Verily, an Alphabet precision health company are joining forces to advance skin health. The partnership is expected to entail two programs aimed to better understand and characterize skin and hair aging mechanisms and to inform L'Oréal's precis
- UCB Releases Positive Top-line Results for Bimekizumab in Second Phase 3 Psoriatic Arthritis Studyhttps://practicaldermatology.com/news/ucb-releases-positive-top-line-results-for-bimekizumab-in-second-phase-3-psoriatic-arthritis-study/2461047/UCB’s bimekizumab performed well in a Phase 3 study of active psoriatic arthritis patients who were inadequate responders or intolerant to anti-tumor necrosis factor-alpha (anti-TNF-α) therapy. Significantly more patients treated with bimekizumab achieved 50 percent or great
- DecisionDx-SCC Performs Well as a Risk-Stratification Tool in Patients with High-risk SCChttps://practicaldermatology.com/news/decisiondx-scc-performs-well-as-a-risk-stratification-tool-in-patients-with-high-risk-scc/2461039/Castle Biosciences, Inc’s DecisionDx-SCC can provide significant and independent prognostic value for stratifying metastasis risk in patients with cutaneous squamous cell carcinoma (SCC) with one or more risk factors (high risk), a new study shows. The study appears in&nb
- FDA Approves Pfizer's Cibinqo for Moderate-to-Severe AD in Adultshttps://practicaldermatology.com/news/fda-approves-pfizers-cibinqo-for-moderate-to-severe-ad-in-adults/2461037/Pfizer's Cibinqo® (abrocitinib), an oral, once-daily, Janus kinase 1 (JAK1) inhibitor, is now FDA approved for the treatment of adults with refractory, moderate-to-severe atopic dermatitis (AD) whose disease is not adequately controlled with other systemic drug products, including bi
- FDA Approves Rinvoq for Adults and Children 12 Years and Older with Refractory, Moderate to Severe ADhttps://practicaldermatology.com/news/us-fda-approves-rinvoq-for-adults-and-children-12-years-and-older-with-refractory-moderate-to-severe-ad/2461036/The FDA has given its nod to AbbVie’s Rinvoq (upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including bio
- $511M SPAC Deal for Sunevahttps://practicaldermatology.com/news/511m-spac-deal-for-suneva/2461032/Suneva Medical, Inc. and Viveon Health Acquisition Corp., a special purpose acquisition company (SPAC), are joining forces to form a regenerative aesthetics company. Upon completion of the transaction, the combined company's securities are expected to be traded on the NYSE unde
- Lilly's Lebrikizumab Plus Topical Corticosteroids Offer Improvement and Itch Relief in Atopic Dermatitishttps://practicaldermatology.com/news/lillys-lebrikizumab-plus-topical-corticosteroids-offer-improvement-and-itch-relief-in-atopic-dermatitis/2461015/Lebrikizumab, an IL-13 inhibitor, significantly improved disease severity when combined with topical corticosteroids (TCS) in people with moderate-to-severe atopic dermatitis (AD) in Eli Lilly and Company's third pivotal Phase 3 trial (ADhere). By Week 16, the study met all primary and k
- Allergan Aesthetics Completes Acquisition of Solitonhttps://practicaldermatology.com/news/allergan-aesthetics-completes-acquisition-of-soliton/2461013/It’s official: Allergan Aesthetics, an AbbVie company, completed its acquisition of Soliton, Inc. The addition of Soliton and its technology complements Allergan Aesthetics' portfolio of non-invasive body contouring treatments to now include the RESONIC device.